Abstract
The study has established that during a progressive tuberculous process, immunological changes appear as significant increased proinflammatory cytokine production that leads to progressive destructive processes in the lung parenchymal lesion areas. Inclusion of lymphotrophic chemoimmunotherapy with roncoleukin into the complex therapy of patients with progressive pulmonary tuberculosis permits the optimization of the results of treatment in patients with progressive pulmonary tuberculosis due to the target delivery of antituberculous and immunoactive agents.
Publication types
-
Comparative Study
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Adolescent
-
Adult
-
Antitubercular Agents / administration & dosage*
-
Antitubercular Agents / pharmacokinetics
-
Disease Progression
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Female
-
Follow-Up Studies
-
Humans
-
Injections, Intralymphatic
-
Interleukin-2 / administration & dosage*
-
Interleukin-2 / pharmacokinetics
-
Lymph Nodes / metabolism
-
Lymph Nodes / pathology*
-
Lymphography
-
Male
-
Middle Aged
-
Prospective Studies
-
Recombinant Proteins
-
Thorax
-
Tomography, X-Ray Computed
-
Treatment Outcome
-
Tuberculosis, Pulmonary / diagnosis
-
Tuberculosis, Pulmonary / drug therapy*
-
Tuberculosis, Pulmonary / metabolism
-
Young Adult
Substances
-
Antitubercular Agents
-
Interleukin-2
-
Recombinant Proteins